# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN-TD
- Date: 1996-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Moreau, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Establishing primary care for Parkinson's disease: motor, non-motor, fall-risk, and orthostatic assessment. **S**

## Historical basis

- Muhammad Ali was born Cassius Clay in Louisville, Kentucky, on January 17, 1942. **D**
- In 1984, at age 42 and three years after he retired from boxing, Ali was diagnosed with a parkinsonian condition by the neurologist Stanley Fahn in New York; it has been publicly described as Parkinson's disease since. **D**
- The diagnosing neurologist later said publicly that slowness of movement was Ali's main limitation at the time of diagnosis, with a masked face, decreased blinking, a typical parkinsonian tremor, and a shuffling gait, and that some features were too early for classic Parkinson's disease. **D**
- In a 1996 television interview, Ali's physician Dennis Cope described his condition as Parkinson's syndrome attributed to pugilistic brain syndrome from boxing, and said testing showed his cognitive function had not declined: "His mind is fine." **D**
- Whether boxing caused Ali's Parkinson's disease is disputed. The diagnosing neurologist thought the early symptoms were probably caused by repeated blows to the head but could not be certain; his later physician Abraham Lieberman did not think boxing contributed, though he was not a hundred percent certain; and the director of the Muhammad Ali Parkinson Center said there was no medical evidence that boxing contributed. **R**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- He wants to stay steady on his feet and keep making public appearances. **S**
- People in crowds have trouble hearing him because his voice is soft. **S**

## Strengths and supports

- Supports: spouse, adult children, and long-time friends and staff who travel with him **S**

## Medications and allergies

- Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1981: Professional boxing career with repeated blows to the head, ended by retirement in 1981; whether it caused his Parkinson's disease is disputed **R** (CLM-0003, CLM-0006)
- 1984: Parkinsonian condition diagnosed in 1984, at 42, by a neurologist in New York, with slowness of movement, a masked face, decreased blinking, tremor, and a shuffling gait **D** (CLM-0003, CLM-0004)

## Procedures and immunizations

- No procedures before this visit. **S**
- 1995-10-14: Influenza vaccine, 1995-1996 season **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 14.6 g/dL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 87 mL/min/1.73 m²; Glucose: 92 mg/dL; Calcium: 9.5 mg/dL; Vitamin B12: 512 pg/mL; TSH: 1.8 mIU/L; MoCA: 27; PHQ-9: 3. All results are synthetic.

BP 128/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 28 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert and fully oriented; humorous and engaged; speech soft and slow but fluent and coherent; MoCA 27 of 30; Mood good; PHQ-9 score 3; no hallucinations or delusions. Functional status: At the first visit, in the on state about two hours after a levodopa dose: Hoehn and Yahr stage 2.5; MDS-UPDRS Part III 30. Bilateral bradykinesia and rigidity, worse on the right; right-hand rest tremor; reduced facial expression and blinking; soft, monotone speech; reduced arm swing with short steps; recovers unaided on the pull test after three steps. No dyskinesia, wearing-off, or freezing; Falls: none in the past year and no near falls; Timed Up and Go 13 seconds without an aid; Orthostatic check at the first visit: 130/80 mmHg, pulse 70, after 5 minutes supine; 122/78 mmHg, pulse 76, after 3 minutes standing, without symptoms; no orthostatic hypotension; Non-motor screens at the first visit: EAT-10 swallowing screen 2 (below the threshold of 3), no choking or coughing with meals; no dream enactment on the RBD screening questionnaire; Epworth Sleepiness Scale 6; no constipation, urinary urgency, or lightheadedness; no hallucinations; impulse-control screen (QUIP-RS) negative; Independent in all activities of daily living; buttoning and handwriting are slow; drives only short local trips in daylight. Physical examination is intentionally limited. **S**

## Assessment

1. Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations; status draft. **S**
2. Hypokinetic dysarthria with soft speech due to Parkinson's disease; status draft. **S**

## Plan

- Review the levodopa dose and timing at every visit for slowness, wearing-off, and dyskinesia; take doses 30 minutes before meals; check supine and three-minute standing blood pressure after any change; avoid dopamine-blocking drugs such as metoclopramide, prochlorperazine, and most antipsychotics. Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Movement disorders neurology consultation to confirm the diagnosis against the MDS criteria, adjust levodopa, plan rehabilitation, and advise on genetic testing. Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Monitor on the CMID schedule: motor examination, Hoehn and Yahr stage, fall check, psychosis and impulse-control questions, and medication review every visit; cognition, mood, sleep, autonomic symptoms, swallowing, speech, and driving yearly; dental examination every six months. Guideline: MDS clinical diagnostic criteria for Parkinson's disease (2015); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Advance care planning: name a health care agent and record goals of care, and revisit with any change in stage. Guideline: CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**

## Guideline basis

- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021), American Academy of Neurology (Neurology)
- MDS clinical diagnostic criteria for Parkinson's disease (2015), International Parkinson and Movement Disorder Society (Movement Disorders)
- The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017), American Autonomic Society and National Parkinson Foundation (Journal of Neurology)
- CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026), Aether Forge
